Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$67.86

-8.13 (-10.70%)

13:17
11/23/16
11/23
13:17
11/23/16
13:17

Eli Lilly price target lowered to $73 from $88 at Morgan Stanley

Morgan Stanley analyst David Risinger lowered his price target for Eli Lilly to $73 after removing Alzheimer's candidate solanezumab from his model. Following this morning's Phase 3 failure, the analyst keeps an Equal Weight rating on the shares. The next catalyst for Eli Lilly is the FDA's action on Jardiance's label by December 4, Risinger tells investors in a research note. He expects Jardiance to get a CV death reduction indication. The analyst notes that his and consensus 2020 estimates have "significant downside" should the indication not be granted. Lilly is down 11%, or $8.28, to $67.71 in afternoon trading.

  • 04

    Dec

LLY Eli Lilly
$67.86

-8.13 (-10.70%)

11/23/16
JPMS
11/23/16
NO CHANGE
Target $85
JPMS
Overweight
JPMorgan sees 'attractive opportunity' amid Eli Lilly selloff
JPMorgan analyst Chris Schott lowered his price target for Eli Lilly to $85 from $95 after the phase III trial of solanezumab missed on both primary and secondary endpoints. Beyond solanezumab, Lilly has a diverse range of new product opportunities that support 5% sales and mid-teens earnings growth, Schott tells investors in a research note. With the shares down 13% to $65.81 in pre-market trading, the analyst sees an "attractive opportunity." He keeps an Overweight rating on Lilly.
11/23/16
JEFF
11/23/16
NO CHANGE
Target $100
JEFF
Buy
Eli Lilly still expects to grow revenue, says Jefferies
Jefferies analyst Jeffrey Holford says that while the solanezumab Phase III trial failure is disappointing, Eli Lilly management expects to grow revenue between 2015 and 2020 while expanding margins. Further, the company is still pursuing the Alzheimer's indication though a number of other programs, Holford tells investors in a research note. The analyst previously estimated a negative solanezumab trial outcome could see the stock down $12. Shares of Lilly are currently down $10.19 to $65.80 in pre-market trading. Holford keeps a Buy rating on Lilly with a $100 price target.
11/23/16
SBSH
11/23/16
NO CHANGE
Target $305
SBSH
Buy
Citi sees four reasons why Biogen Alzheimer's drug can still work
Citi analyst Robyn Karnauska sees four reasons why Biogen's (BIIB) Alzheimer's drug aducanumab can still work following the failure of Eli Lilly's (LLY) solanezumab. The analyst lists difference in mechanism of action, efficacy in an end-point-dependent manner, patient population and endpoints as why she thinks Biogen's drug can have a different outcome than Lilly's. The analyst has a Neutral rating on Biogen with a $305 price target.
11/23/16
JEFF
11/23/16
NO CHANGE
Target $310
JEFF
Buy
Biogen selloff may be an overreaction, says Jefferies
Jefferies analyst Brian Abrahams believes selloff in shares of Biogen (BIIB) following Eli Lilly's (LLY) Alzheimer's failure may be an overreaction. Signals of activity seen for Lilly's sola "do maintain some possibility" that Biogen's aducanumab could "ultimately make it over the line," Abrahams tells investors in a research note. He keeps a Hold rating on Biogen with a $310 price target, however, viewing the risk/reward as balanced.

TODAY'S FREE FLY STORIES

HCLP

Hi-Crush Partners

$22.97

1.5705 (7.34%)

12:26
02/22/17
02/22
12:26
02/22/17
12:26
Upgrade
Hi-Crush Partners rating change  »

Wunderlich upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

PAA

Plains All American

$30.57

-0.67 (-2.14%)

12:26
02/22/17
02/22
12:26
02/22/17
12:26
Options
Plains All American call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 08

    Aug

  • 08

    Nov

12:25
02/22/17
02/22
12:25
02/22/17
12:25
General news
Euro$ interest rate futures stalled out »

Euro$ interest rate…

12:25
02/22/17
02/22
12:25
02/22/17
12:25
Conference/Events
Forecasters Club of New York to hold a luncheon meeting »

Federal Reserve Governor…

USPH

U.S. Physical Therapy

$74.55

-1.55 (-2.04%)

12:25
02/22/17
02/22
12:25
02/22/17
12:25
Conference/Events
CFA Society of Houston to hold a luncheon meeting »

Chris Reading, CEO of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 21

    Mar

  • 29

    Mar

  • 11

    Apr

  • 12

    Apr

PUGOY

Peugeot

$19.40

-0.215 (-1.10%)

, GM

General Motors

$37.86

0.05 (0.13%)

12:23
02/22/17
02/22
12:23
02/22/17
12:23
Periodicals
PSA Group targets up to $2.1B in cost savings from Opel deal, Reuters says »

Peugeot (PUGOY) parent…

PUGOY

Peugeot

$19.40

-0.215 (-1.10%)

GM

General Motors

$37.86

0.05 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

SCOR

comScore

$24.42

0.12 (0.49%)

12:21
02/22/17
02/22
12:21
02/22/17
12:21
Conference/Events
comScore to host business news update conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 24

    Feb

BA

Boeing

$175.52

-0.04 (-0.02%)

, LMT

Lockheed Martin

$264.87

-0.79 (-0.30%)

12:19
02/22/17
02/22
12:19
02/22/17
12:19
Periodicals
Key lawmaker: Trump jet competition 'doesn't make sense,' Bloomberg reports »

Speaking in a Bloomberg…

BA

Boeing

$175.52

-0.04 (-0.02%)

LMT

Lockheed Martin

$264.87

-0.79 (-0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

$NSD

NASDAQ Market Internals

12:17
02/22/17
02/22
12:17
02/22/17
12:17
Technical Analysis
NASDAQ Market Internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:17
02/22/17
02/22
12:17
02/22/17
12:17
Technical Analysis
NYSE Market Internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$119.46

-0.2 (-0.17%)

12:17
02/22/17
02/22
12:17
02/22/17
12:17
Conference/Events
Johnson & Johnson hs a conference call hosted by JPMorgan »

JPMorgan Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 24

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

12:15
02/22/17
02/22
12:15
02/22/17
12:15
General news
FX Action: USD-JPY »

FX Action: USD-JPY traded…

UN

Unilever; also tag UL

$46.74

1.65 (3.66%)

, UL

Unilever; also tag UN

$46.99

2.12 (4.72%)

12:14
02/22/17
02/22
12:14
02/22/17
12:14
General news
On The Fly: Top stock stories at midday »

Stocks opened in negative…

UN

Unilever; also tag UL

$46.74

1.65 (3.66%)

UL

Unilever; also tag UN

$46.99

2.12 (4.72%)

KHC

Kraft Heinz

$94.87

-1.78 (-1.84%)

TJX

TJX

$76.00

-0.245 (-0.32%)

GRMN

Garmin

$50.45

-0.36 (-0.71%)

TOL

Toll Brothers

$34.04

2.05 (6.41%)

DEPO

Depomed

$15.77

-0.7 (-4.25%)

CHS

Chico's

$14.93

0.635 (4.44%)

PZZA

Papa John's

$85.63

-0.38 (-0.44%)

TXRH

Texas Roadhouse

$47.79

-0.45 (-0.93%)

FSLR

First Solar

$36.62

1.78 (5.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 19

    Mar

INGIY

Ingenico

$16.94

0.02 (0.12%)

12:06
02/22/17
02/22
12:06
02/22/17
12:06
Hot Stocks
Ingenico finalizes acquisition of TechProcess; terms not disclosed »

Ingenico Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

HCLP

Hi-Crush Partners

$23.05

1.65 (7.71%)

12:06
02/22/17
02/22
12:06
02/22/17
12:06
Upgrade
Hi-Crush Partners rating change  »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

12:05
02/22/17
02/22
12:05
02/22/17
12:05
General news
Treasury's $13 B 2-year FRN reopening was mixed »

Treasury's $13 B…

NFX

Newfield Exploration

$39.62

-2.87 (-6.75%)

12:01
02/22/17
02/22
12:01
02/22/17
12:01
Options
Newfield Exploration puts active as shares fall on earnings »

Newfield Exploration puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

11:59
02/22/17
02/22
11:59
02/22/17
11:59
Conference/Events
JPMorgan biotech/biopharma analysts hold an analyst/industry conference call »

SMid Biotech Analyst…

TWTR

Twitter

$16.33

-0.09 (-0.55%)

11:59
02/22/17
02/22
11:59
02/22/17
11:59
Hot Stocks
Twitter director of finance David Bicknell resigns »

David Bicknell, director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 28

    Feb

  • 19

    Mar

PSX

Phillips 66

$78.29

-0.7425 (-0.94%)

11:56
02/22/17
02/22
11:56
02/22/17
11:56
Options
Phillips 66 put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLB

Dolby

11:54
02/22/17
02/22
11:54
02/22/17
11:54
Conference/Events
Dolby management to meet with William Blair »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Feb

  • 28

    Mar

TREX

Trex Company

$66.58

-4.57 (-6.42%)

11:53
02/22/17
02/22
11:53
02/22/17
11:53
Conference/Events
Trex Company management to meet with Stephens »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

P

Pandora

$13.08

-0.065 (-0.49%)

11:52
02/22/17
02/22
11:52
02/22/17
11:52
Conference/Events
Pandora management to meet with B. Riley »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 28

    Feb

  • 19

    Mar

CARB

Carbonite

$19.65

0.05 (0.26%)

11:50
02/22/17
02/22
11:50
02/22/17
11:50
Conference/Events
Carbonite management to meet with Lake Street »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 27

    Feb

RP

RealPage

$34.35

-0.2 (-0.58%)

11:50
02/22/17
02/22
11:50
02/22/17
11:50
Hot Stocks
RealPage announces new multi-year agreement with Morgan Properties »

RealPage announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.